Latest News and Press Releases

Year marked by operational and clinical execution advancing the development of a potential breakthrough technology for the nervous system Continued progress in first study ever to evaluate...

Results from the preclinical study demonstrated statistically significant reduction of metastases and statistically significant reduction in tumor mass Lori Bisson, Chief Executive Officer...

Live webcast on Thursday, May 16th at 4:00 PM ET THE WOODLANDS, TX, May 14, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company...

THE WOODLANDS, TX, April 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to...

Live webcast on Wednesday, May 1st at 3:20 PM ET THE WOODLANDS, TX, April 24, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device...

Patent portfolio with over 100 patents, issued and pending, protects technology targeting a $100 billion market opportunity Company developing potential breakthrough two-fold technology that can...

Preclinical study demonstrates potential of Autonomix technology to make renal denervation safer and more effective Ongoing advancement of sensing and ablation technologies toward proof-of-concept...

Live webcast with members of the Autonomix management team, on Thursday, April 11th at 12:00 PM ET THE WOODLANDS, TX, April 08, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX)...

Live webcast presentation on Thursday, April 4th at 3:55 PM ET THE WOODLANDS, TX, March 27, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a...

Live webcast presentation on Wednesday, March 20th at 11:50 AM ET THE WOODLANDS, TX, March 20, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a...